AIM ImmunoTech (AIM) investor relations material

Executive summary

• Q3 revenue was $22k and net loss was $3.1m; 9M revenue was $70k and net loss was $10.0m. Cash, cash equivalents and marketable securities totaled $6.9m at September 30, 2026.

• Strategic focus remains Ampligen development for late-stage pancreatic cancer, with DURIPANC Phase 2 enrollment complete and all subjects finished Ampligen treatment; durvalumab treatment continues.

Financial highlights

• Q3 total costs and expenses rose to $3.0m from $2.5m YoY; operating loss widened to $3.0m from $2.4m.

• Q3 net loss narrowed to $3.1m from $3.3m YoY; prior-year results included a $4.0m warrant issuance loss and $3.0m one-time legal-fee settlement gain in other income.

• 9M operating loss was $8.7m, compared with $8.7m in 2025; net loss increased to $10.0m from $9.8m, with higher equity-offering costs partly offset by lower R&D.

• 9M revenue increased to $70k from $67k; Q3 revenue was $22k versus $26k YoY, all from U.S. clinical treatment programs.

Outlook and guidance

• DURIPANC topline results are anticipated in Q1 2027, with overall-survival analysis expected in Q3 2027; Phase 3 planning is underway with PPD, following study completion and protocol finalization.

• Short-term annual working-capital needs are estimated at $7.2m–$10.8m; available cash and securities are expected to fund operations only into 2027, requiring additional capital beyond then.

• Next-12-month cash requirements include pancreatic-cancer trials, approximately $1.5m of Sterling manufacturing payments, leases and roughly $1.7m of Streeterville note principal.

• AMP-270 pancreatic-cancer enrollment remains on hold; potential redesign depends on additional DURIPANC data.